ISSUE 2 : FEBRUARY 2019

The Veeda Newsletter

INDIAN PHARMA

India: USFDA Records Highest Number Of Novel Drug Approvals In 2018

The approval and launch of new medicines/biological products for marketing often means the availability of new treatment for patients and advancement in health care.
Read more at: http://www.mondaq.com/india/x/784030/Healthcare/USFDA+records+highest+number+of+Novel+Drug+approvals+in+2018


Compulsory Licensing of Pharmaceutical Patents in India

The trend of continued rejection of compulsory license applications in India goes against the local generic drug manufacturers and public health safeguards incorporated in the Indian patent law.
Read more : : https://www.epw.in/journal/2019/5/commentary/compulsory-licensing-pharmaceutical.html

Indian drugmakers urged to tap cancer market and innovation

Shifting focus from generic drugs to specialty drugs amidst continued price erosion in the USA, Indian.
Read more : https://www.thepharmaletter.com/article/indian-drugmakers-urged-to-tap-cancer-market-and-innovation

Indian pharma players need to explore new regions for exports

Indian pharma industry, worth $34 billion in 2018, has exhibited huge potential and is expected to grow at a compound annual growth rate (CAGR) of 15 per cent.
Read more : https://www.theweek.in/news/biz-tech/2019/02/18/Indian-pharma-players-need-to-explore-new-regions-for-exports.html


New rules sweeten the deal for clinical trials by Indian pharma cos

The latest set of clinical trial rules, likely to be notified in March, will fast-track proposal clearances for Indian companies rather than their multinational counterparts.
Read more : https://www.thehindubusinessline.com/news/new-rules-sweeten-the-deal-for-clinical-trials-by-indian-pharma-cos/article26283499.ece

www.veedacr.com
info@veedacr.com
Contact Us